187 related articles for article (PubMed ID: 38792849)
1. Role of Probiotics in Gut Microbiome and Metabolome in Non-Alcoholic Fatty Liver Disease Mouse Model: A Comparative Study.
Wu T; Zeng Z; Yu Y
Microorganisms; 2024 May; 12(5):. PubMed ID: 38792849
[TBL] [Abstract][Full Text] [Related]
2.
Banerjee G; Papri SR; Satapathy SK; Banerjee P
Curr Pharm Biotechnol; 2024; 25(4):426-433. PubMed ID: 37724669
[TBL] [Abstract][Full Text] [Related]
3. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
4. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H
Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.
Lin D; Sun Q; Liu Z; Pan J; Zhu J; Wang S; Jia S; Zheng M; Li X; Gong F
Free Radic Biol Med; 2023 Feb; 195():199-218. PubMed ID: 36586452
[TBL] [Abstract][Full Text] [Related]
6. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.
Ye JZ; Li YT; Wu WR; Shi D; Fang DQ; Yang LY; Bian XY; Wu JJ; Wang Q; Jiang XW; Peng CG; Ye WC; Xia PC; Li LJ
World J Gastroenterol; 2018 Jun; 24(23):2468-2481. PubMed ID: 29930468
[TBL] [Abstract][Full Text] [Related]
7. Effects of cholesterol-lowering probiotics on non-alcoholic fatty liver disease in FXR gene knockout mice.
Yang M; Wang H; Bukhari I; Zhao Y; Huang H; Yu Y; Sun X; Mi Y; Mei L; Zheng P
Front Nutr; 2023; 10():1121203. PubMed ID: 37545590
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel probiotic and its protective effects on NAFLD via modulating gut microbial community.
Geng W; Zhang Y; Yang J; Zhang J; Zhao J; Wang J; Jia L; Wang Y
J Sci Food Agric; 2022 Aug; 102(11):4620-4628. PubMed ID: 35174500
[TBL] [Abstract][Full Text] [Related]
9. Xie Zhuo Tiao Zhi formula modulates intestinal microbiota and liver purine metabolism to suppress hepatic steatosis and pyroptosis in NAFLD therapy.
Qiu J; Chen L; Zhang L; Xu F; Zhang C; Ren G; Chang K; He G; Du Z; Le Y; Yu Z; Li S; Liu Q; Dou X
Phytomedicine; 2023 Dec; 121():155111. PubMed ID: 37804819
[TBL] [Abstract][Full Text] [Related]
10. Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.
Luo M; Yan J; Wu L; Wu J; Chen Z; Jiang J; Chen Z; He B
J Immunol Res; 2021; 2021():2264737. PubMed ID: 34458376
[TBL] [Abstract][Full Text] [Related]
11.
Nian F; Wu L; Xia Q; Tian P; Ding C; Lu X
J Clin Transl Hepatol; 2023 Aug; 11(4):763-776. PubMed ID: 37408808
[TBL] [Abstract][Full Text] [Related]
12. The Protective Effects of Live and Pasteurized Akkermansia muciniphila and Its Extracellular Vesicles against HFD/CCl4-Induced Liver Injury.
Keshavarz Azizi Raftar S; Ashrafian F; Yadegar A; Lari A; Moradi HR; Shahriary A; Azimirad M; Alavifard H; Mohsenifar Z; Davari M; Vaziri F; Moshiri A; Siadat SD; Zali MR
Microbiol Spectr; 2021 Oct; 9(2):e0048421. PubMed ID: 34549998
[TBL] [Abstract][Full Text] [Related]
13.
Huang Y; Cao J; Zhu M; Wang Z; Jin Z; Xiong Z
Microbiol Spectr; 2024 Apr; 12(4):e0339323. PubMed ID: 38411057
[TBL] [Abstract][Full Text] [Related]
14. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
15. Tangshen formula targets the gut microbiota to treat non-alcoholic fatty liver disease in HFD mice: A 16S rRNA and non-targeted metabolomics analyses.
Wang S; Li X; Zhang B; Li Y; Chen K; Qi H; Gao M; Rong J; Liu L; Wan Y; Dong X; Yan M; Ma L; Li P; Zhao T
Biomed Pharmacother; 2024 Apr; 173():116405. PubMed ID: 38484559
[TBL] [Abstract][Full Text] [Related]
16. Heat-Inactivated
Morrison MC; Gart E; Duyvenvoorde WV; Snabel J; Nielsen MJ; Leeming DJ; Menke A; Kleemann R
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216439
[TBL] [Abstract][Full Text] [Related]
17. The Synbiotic Combination of
Juárez-Fernández M; Porras D; Petrov P; Román-Sagüillo S; García-Mediavilla MV; Soluyanova P; Martínez-Flórez S; González-Gallego J; Nistal E; Jover R; Sánchez-Campos S
Antioxidants (Basel); 2021 Dec; 10(12):. PubMed ID: 34943104
[TBL] [Abstract][Full Text] [Related]
18. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
Miura K; Ohnishi H
World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
[TBL] [Abstract][Full Text] [Related]
19. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
Safari Z; Gérard P
Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
[TBL] [Abstract][Full Text] [Related]
20. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
